Clinical trials: Advanced Digestive System Tumor
Esophageal Squamous Cell Carcinoma
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of dalpiciclib combined with pyrotinib as second-line therapy in patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06684600
- Testing
- Dalpiciclib + Pyrotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking University
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer
This observational study is a follow-up study of protocol ML18280. Survival data of patients who took part in and concluded study ML18280 will be collected for up to 5 years after LPLV of ML18270.
- Trial name
- NCT01339832
- Where
- 5 sites in Switzerland
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
Study of EOC317 in Chinese Patients With Advanced Solid Tumors
This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.
- Trial name
- NCT03583125
- Testing
- EOC317
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Solid Tumor, Breast Cancer
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
The purpose of this study is to determine the safety profile, including the maximum tolerated dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer patients with advanced solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT01041235
- Testing
- ATI-1123 (active drug = docetaxel)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Azaya Therapeutics, Inc.
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006117
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 10 sites in Belgium, France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
Recurrent Breast Cancer, Recurrent Colon Cancer
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors.
- Conditions
- Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer
- Trial name
- NCT01987726
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Liver Tumor
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.
- Trial name
- NCT05555316
- Testing
- TACE combined with Lenvatinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Neoplasms, Pancreatic Neoplasms
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
- Trial name
- NCT00102752
- Testing
- Glufosfamide, Gemcitabine
- Where
- 9 sites in United States, Brazil
- Volunteers
- 47 people
- Sponsor
- Threshold Pharmaceuticals
Hepatocellular Carcinoma, Liver Cancer
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
- Trial name
- ET-109 (NCT03998033)
- Testing
- ET140202 autologous T cell product
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Eureka Therapeutics Inc.
Pancreatic Cancer, Pancreatic Neoplasms
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation and HLA-A*11:01 allele.
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
- Trial name
- NCT04146298
- Testing
- Cyclophosphamide, Fludarabine, Mutant KRAS G12V-specific TCR transduced autologous T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Neoplasms, Neoplasm Metastasis
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
- Conditions
- Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT02014116
- Testing
- LY3009120 capsule
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with…
- Trial name
- NCT01041404
- Testing
- Trastuzumab, Fluorouracil, Cisplatin
- Where
- 142 sites in Australia, Belgium and 22 more
- Volunteers
- 584 people
- Sponsor
- Hoffmann-La Roche
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Pancreatic Cancer
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1.
- Trial name
- NCT00831493
- Testing
- Chemoradiation (Radiation Therapy), Vorinostat
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
A significant proportion of advanced gastric cancer (AGC) occurs in individuals 65 years of age and older. In addition, patient delay in seeking care for symptoms results in diagnosis at a more advanced stage than that seen in…
- Trial name
- NCT00278863
- Testing
- S-1, Capecitabine
- Where
- 9 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00112632
- Testing
- imatinib mesylate, conventional surgery, neoadjuvant therapy
- Where
- 9 sites in Austria, Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.